Can you provide the last earnings date for SUPERNUS PHARMACEUTICALS INC?
SUPERNUS PHARMACEUTICALS INC (SUPN) last reported earnings on 2/24/2026.
NASDAQ:SUPN • US8684591089
Past quarterly earnings results for SUPERNUS PHARMACEUTICALS INC (SUPN), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 0.84 | 0.35 | 142.21% | 12.00% | 211.572M | 198.9M | 6.37% | 21.48% |
| Q3 2025 | 1.01 | 0.60 | 67.83% | -13.68% | 192.103M | 182.47M | 5.28% | 9.34% |
| Q2 2025 | 0.90 | 0.48 | 87.73% | 16.88% | 165.453M | 157.14M | 5.29% | -1.71% |
| Q1 2025 | 0.44 | 0.38 | 15.55% | 69.23% | 149.824M | 150.89M | -0.71% | 4.30% |
| Q4 2024 | 0.75 | 0.42 | 77.18% | -15.73% | 174.159M | 158.36M | 9.98% | 5.99% |
| Q3 2024 | 1.17 | 0.45 | 158.74% | 387.50% | 175.689M | 160.44M | 9.50% | 14.17% |
| Q2 2024 | 0.77 | 0.40 | 93.56% | 3,950.00% | 168.325M | 151.83M | 10.86% | 24.17% |
| Q1 2024 | 0.26 | 0.38 | -32.33% | -10.34% | 143.644M | 148.75M | -3.43% | -6.58% |
| Q4 2023 | 0.89 | 0.56 | 57.69% | 106.98% | 164.314M | 158.13M | 3.91% | -1.78% |
| Q3 2023 | 0.24 | 0.08 | 194.12% | 700.00% | 153.88M | 146.25M | 5.22% | -13.26% |
| Q2 2023 | -0.02 | 0.07 | -130.17% | -114.29% | 135.563M | 146.53M | -7.48% | -20.30% |
| Q1 2023 | 0.29 | 0.17 | 67.24% | -32.56% | 153.764M | 141.8M | 8.44% | 0.83% |
| Q4 2022 | 0.43 | 0.69 | -38.00% | 975.00% | 167.3M | 183.98M | -9.07% | 5.15% |
| Q3 2022 | 0.03 | 0.36 | -91.75% | -92.50% | 177.4M | 175.93M | 0.84% | 19.46% |
| Q2 2022 | 0.14 | 0.30 | -52.67% | -67.44% | 170.1M | 167.51M | 1.55% | 20.38% |
| Q1 2022 | 0.43 | 0.24 | 75.65% | 290.91% | 152.5M | 153.48M | -0.64% | 16.50% |
| Q4 2021 | 0.04 | 0.24 | -83.43% | -92.98% | 159.1M | 155.77M | 2.14% | 10.79% |
| Q3 2021 | 0.40 | 0.24 | 68.67% | -45.95% | 148.5M | 144.96M | 2.44% | -4.26% |
| Q2 2021 | 0.43 | 0.20 | 113.45% | -33.85% | 141.3M | 137.57M | 2.71% | 11.52% |
| Q1 2021 | 0.11 | 0.25 | -55.53% | -72.50% | 130.9M | 131.78M | -0.67% | 37.79% |
| Q4 2020 | 0.57 | 0.53 | 7.99% | - | 143.6M | 149.11M | -3.70% | - |
| Q3 2020 | 0.74 | 0.30 | 143.86% | - | 155.1M | 133.27M | 16.38% | - |
| Q2 2020 | 0.65 | 0.43 | 51.73% | - | 126.7M | 100.06M | 26.62% | - |
| Q1 2020 | 0.40 | 0.29 | 39.06% | - | 95M | 85.151M | 11.57% | - |
Notes
SUPERNUS PHARMACEUTICALS INC (SUPN) last reported earnings on 2/24/2026.
SUPERNUS PHARMACEUTICALS INC (SUPN) beat EPS estimates and beat revenue estimates in the most recent quarter.
In the last 4 quarters, SUPERNUS PHARMACEUTICALS INC (SUPN) has beaten EPS estimates in 4 out of 4 releases.